# A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

Study · id `cardio:ct-nct01153815` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01153815](<https://clinicaltrials.gov/study/NCT01153815>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01153815

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

## Technical summary

Registry record NCT01153815. Randomized; quadruple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-05-17.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 170 participants (enrolled count; ClinicalTrials.gov record NCT01153815, source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01153815, source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)
- Primary completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01153815, source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)
- Completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01153815, source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)
- Results first posted: 2012-05-17 (ClinicalTrials.gov record NCT01153815, source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01153815, source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01153815-2017-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
- Condition: Cerebrovascular Accident
- Intervention (Drug): GSK1358820(Botulinum toxin type A)
- Intervention (Drug): placebo
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 2a3dc6d8908e2092db0acc96b1653458eca7fae52fdc7c41d5b823c6659830c6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
